We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Not every hot ophthalmology innovation is built to stand ...

There is no cure for keratoconus, but the cornea can be strengthened to slow or halt the progression of the disease with an FDA-approved cross-linking procedure called iLink®. Once diagnosed, there is ...

Patients in Somerset with keratoconus, an eye condition that causes blurred vision and sensitivity to light, can now access ...

Please provide your email address to receive an email when new articles are posted on . NEW YORK — Advancements in cross-linking will involve performing the procedure with the epithelium on, Mitch ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...

The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, ...